| Description | This product is a human monoclonal antibody that reacts with SIRPA. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG4 |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | DB; WB; ELISA |
| Application Notes | The antibody is recommended for detection of SIRPA by WB, ELISA assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SIRPA |
| Alternative Name | SIRPA; signal-regulatory protein alpha; BIT; MFR; P84; SIRP; MYD-1; SHPS1; CD172A; PTPNS1; tyrosine-protein phosphatase non-receptor type substrate 1; myd-1 antigen; inhibitory receptor SHPS-1; macrophage fusion receptor; CD172 antigen-like family member A; tyrosine phosphatase SHP substrate 1; brain-immunoglobulin-like molecule with tyrosine-based activation motifs; anti-SIRPA |
| Gene ID | 140885 |
| UniProt | P78324 |
| Research Area | Neuroscience |
Figure 1 Anti-Human SIRPA Monoclonal Antibody (V3S-0622-YC5366) in WB
Western blot analysis of V3S-0622-YC5366 was performed by loading Human SIRPA Protein (His Tag) in reduced condition Lane 1, Lane 2, Lane 3 (0.1 μg 0.3 μg 0.6 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC5366 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.
Figure 1 Anti-Human SIRPA Monoclonal Antibody (V3S-0622-YC5366) in WB
Figure 2 Anti-Human SIRPA Monoclonal Antibody (V3S-0622-YC5366) in DB
Dot Blot analysis of V3S-0622-YC5366 was performed by coating with Human SIRPA Protein (His Tag).
V3S-0622-YC5366 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000)
Figure 2 Anti-Human SIRPA Monoclonal Antibody (V3S-0622-YC5366) in DB
Figure 3 Anti-Human SIRPA Monoclonal Antibody (V3S-0622-YC5366) in ELISA
ELISA analysis of V3S-0622-YC5366 was performed by coating with Human SIRPA Protein (His Tag). Then blocked with BSA and incubated with V3S-0622-YC5366. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 5000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-Human SIRPA Monoclonal Antibody (V3S-0622-YC5366) in ELISA
